ME/CFS Evidence Browser — Classified Studies on Myalgic Encephalomyelitis

101–120 of 214 studies

Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome.

Vercoulen, J H, Swanink, C M, Zitman, F G et al.·Lancet (London, England)·1996

This study tested whether fluoxetine (an antidepressant medication) could help people with ME/CFS feel better. Researchers gave 96 patients either fluoxetine or a placebo for 8 weeks and measured changes in fatigue, mood, sleep, and physical activity. The medication did not improve any of these symptoms compared to placebo, whether or not patients were depressed.

Evidence Atlas

Evidence browser

Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome.

Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial.

Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome.

Testing a Personalised Dysautonomia Management Protocol in Patients with Orthostatic Intolerance and a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome or Long COVID.

Hyperbaric oxygen therapy improves clinical symptoms and functional capacity and modulates thalamic connectivity in ME/CFS: a prospective cohort study.

Association between light exposure patterns and multidimensional health outcomes in individuals with myalgic encephalomyelitis/chronic fatigue syndrome: findings from an observational cross-sectional cohort study.

Underuse of Pharmacologic Therapies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Before Specialist Evaluation.

Use and Perceived Helpfulness of Different Intervention Strategies in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Depression.

Association of rapamycin treatment with the modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in ME/CFS subjects: pilot findings from phase-II observational study.

Medication use and symptomology in North American women with myalgic encephalomyelitis/chronic fatigue syndrome.

Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey.

Predictors of treatment response trajectories to cognitive behavioral therapy for chronic fatigue syndrome: A cohort study.

Robuvit® reduces fatigue after chemotherapy for colon cancer. A pilot registry study.

The relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome.

Treatments of chronic fatigue syndrome and its debilitating comorbidities: a 12-year population-based study.

Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole.

Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study.

Cognitive behavioural therapy for chronic fatigue and chronic fatigue syndrome: outcomes from a specialist clinic in the UK.

The Relationship Between Childhood Trauma and the Response to Group Cognitive-Behavioural Therapy for Chronic Fatigue Syndrome.

General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity.

Curated Collections

Neuroinflammation Evidence

Metabolism & Mitochondria

Biomarkers

PEM-Specific Research